U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Shares of Altimmune, Inc. ALT fell sharply in today's pre-market trading after the company announced topline results from the IMPACT Phase 2b trial of Pemvidutide in the treatment of MASH.
Altimmune shares dipped 61.2% to $2.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
- Bit Digital, Inc. BTBT declined 14.9% to $2.0002 in pre-market trading as the company announced the pricing of public offering of its ordinary shares.
- XCF Global, Inc. SAFX fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.
- Kratos Defense & Security Solutions, Inc. KTOS fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.
- Waldencast plc WALD fell 6.3% to $2.53 in pre-market trading.
- Crescent Biopharma, Inc CBIO shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.
- UP Fintech Holding Limited TIGR fell 3.3% to $9.62 in pre-market trading.
- Nokia Oyj NOK fell 2.7% to $5.03 in pre-market trading.
Now Read This:
Photo via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.